Helping you make informed decisions on investing, money, equities and personal finance. Seasoned investors or newbie traders, our financial education corner has something for all.
Firebrick Pharma (ASX:FRE) secures Malaysian patent for nasal spray
Aditi covers content focused on healthcare and food & beverages sectors. She has a post-graduate degree in Genetics and Plant Breeding with Biotechnology as her minor subject. She has two co-authored scientific research publications in peer-reviewed ...
Shwetambri Chauhan is a Sr. Research Editor at Kalkine Media. She comes with an experience of 11 years in secondary research and quality check. Besides, she has rich experience of working across different sectors and markets. Her professional experie...
Innovative Australian pharmaceutical company Firebrick Pharma Limited (ASX:FRE) has added another country to its list of patents covering Nasodine®. The company’s nasal spray (Nasodine) has secured a patent in Malaysia as a treatment and preventative for the common cold.
The latest development brings the total number of countries with patent protection for the nasal spray to 26. Countries which are yet to grant the patent are China, Singapore, Japan, and Canada.
First-in-class nasal spray for common cold
Nasodine® Nasal Spray is Firebrick’s first product, a result of 10 years of development and testing. It is a first-in-class nasal spray medicine that targets the viral cause of the common cold, where colds start – in the nose.
Nasodine contains the broad-spectrum antimicrobial agent, povidone-iodine. It has demonstrated to be well-tolerated as a four-times-daily nasal spray in clinical studies.
The patent is titled “Treatment and prevention of the common cold using povidone-iodine,” and is valid till 2035 in most countries. It safeguards the intranasal use of povidone-iodine (in any form) to treat or prevent the common cold.
Claims being granted to the company are as follows:
Currently, Firebrick is undertaking two clinical trials of Nasodine:
Key addition to the Board
Firebrick has made an important addition to its board with the appointment of Dr Richard Treagus as a non-executive director. He will assume his role from 1 June 2022.
He has an extensive ASX experience and a valuable background in pharmaceutical sales and marketing.
Dr Treagus was previously Commercial Director for Aspen Pharmacare in South Africa, CEO of Acrux Limited (ASX:ACR) and Executive Chairman of Neuren Pharmaceuticals (ASX: NEU).
On WED, 25 MAY 2022, shares of FRE traded at AU$0.390, up over 1% from the last close.
Also read: Can Australia’s new Labor govt heal the cracks within healthcare system?
Copyright © 2022 Kalkine Media Pty Ltd. All Rights Reserved.